Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Receptor Agonists Compared

Few areas of metabolic research have moved as quickly as the incretin field. In the span of a few years, the literature has progressed from single-receptor agonists to dual and now triple receptor agonists — each generation adding a mechanistic arm and, in the reported trials, a larger headline weight-reduction figure. This article compares three compounds that researchers frequently study side by side: semaglutide, tirzepatide, and retatrutide. The goal here is to lay out the mechanistic ladder and the published trial figures for reference, while being explicit about the limits of comparing numbers that come from separate studies.

The Mechanism Ladder: Single, Dual, Triple Agonism

The simplest way researchers frame these three molecules is by counting how many receptor systems each one engages. Semaglutide targets one, tirzepatide targets two, and retatrutide targets three. Each additional arm is thought to recruit a distinct metabolic pathway.

Semaglutide — Single GLP-1 Receptor Agonist

Semaglutide acts on the glucagon-like peptide-1 (GLP-1) receptor alone. In the literature, GLP-1 receptor agonism is associated with reduced appetite and slowed gastric emptying, which together tend to lower caloric intake in the studied populations. It served as the reference point against which the later dual and triple agonists were measured.

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist

Tirzepatide adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor on top of GLP-1. Researchers describe the GIP arm as contributing to insulin sensitization and to effects on adipose tissue that may complement — rather than simply duplicate — GLP-1 signaling. The combination is what the field refers to as dual incretin agonism.

Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist

Retatrutide extends the dual profile by adding glucagon receptor (GCGR) agonism, producing a triple agonist. The glucagon arm is of interest to researchers because glucagon receptor activation in the liver is linked to increased energy expenditure and hepatic fatty acid oxidation. On its own, glucagon agonism could raise blood glucose, but in combination with GLP-1 agonism — which counterbalances that effect — the literature frames it as a lever for energy expenditure rather than a glycemic liability.

What Each Receptor Arm Contributes

Reduced to its components, the mechanistic rationale studied in the literature breaks down roughly as follows:

• GLP-1 receptor: appetite suppression and slowed gastric emptying, reducing caloric intake
• GIP receptor: insulin sensitization and effects on adipose tissue metabolism
• Glucagon (GCGR) receptor: increased energy expenditure and hepatic fatty acid oxidation

The hypothesis that researchers explore is that stacking these arms is additive or synergistic — that engaging appetite, insulin dynamics, and energy expenditure together may reach further than any single pathway alone. Whether that theoretical ceiling holds up in large, long-duration trials remains an active question in the field.

Headline Weight-Loss Figures From the Trials

Each compound has a signature trial that researchers cite. The figures below are drawn directly from those publications and are attributed to the specific dose, study, and duration reported.

• Semaglutide 2.4 mg — approximately 14.9% mean body weight reduction over 68 weeks in STEP 1 (Wilding et al., N Engl J Med 2021)
• Tirzepatide 15 mg — approximately 20.9% mean body weight reduction over 72 weeks in SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022)
• Retatrutide 12 mg — approximately 24.2% mean body weight reduction over 48 weeks in the Phase 2 trial (Jastreboff et al., N Engl J Med 2023)

Side-by-Side Comparison

Cross-Trial Comparison Caveats

It is tempting to read the table as a straight ranking — 14.9%, then 20.9%, then 24.2% — and conclude that each compound is progressively "stronger." That conclusion is not supported by the data, because these numbers come from three separate trials that were never designed to be compared against one another.

Key reasons researchers caution against a direct ranking:

• Not head-to-head: no single trial administered all three compounds to the same population under the same protocol
• Different durations: 68, 72, and 48 weeks respectively — longer or shorter exposure changes the trajectory of the reported outcome
• Different phases and sample sizes: STEP 1 and SURMOUNT-1 are large Phase 3 studies; the retatrutide figure comes from a smaller Phase 2 trial
• Different populations: enrollment criteria, baseline BMI, comorbidities, and demographics varied across studies
• Dose equivalence is not linear: 2.4 mg, 15 mg, and 12 mg are not comparable units — potency per milligram differs by molecule

Because of these differences, the responsible reading is that each compound performed at the level reported within its own study. The figures are useful reference points for the literature, not a leaderboard. Any direct efficacy claim ranking one molecule over another would require a properly designed head-to-head trial, which these datasets are not.

Key Takeaways

• Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist; retatrutide is a triple GIP/GLP-1/glucagon agonist
• Each receptor arm is studied for a distinct contribution: GLP-1 (appetite, gastric emptying), GIP (insulin sensitization, adipose), glucagon (energy expenditure, hepatic fatty acid oxidation)
• Reported headline figures were ~14.9% (semaglutide, STEP 1), ~20.9% (tirzepatide, SURMOUNT-1), and ~24.2% (retatrutide, Phase 2)
• These come from three separate trials — not a head-to-head study — so the numbers should not be read as a direct efficacy ranking
• Differences in duration, phase, sample size, population, and dose equivalence all limit cross-trial comparison
• The triple-agonist rationale — adding an energy-expenditure lever to appetite and insulin pathways — remains an active area of research pending larger, longer trials